腮腺良性和恶性多形性腺瘤的超声研究

目的研究腮腺良性和恶性多形性腺瘤的超声特点,为临床医师诊治提供有效依据。方法选取腮腺良性多形性腺瘤患者79例和恶性多形性腺瘤患者15例,对其肿块的大小、硬度、内部回声、彩色多普勒血流显像(CDFI)特点结合病理学诊断进行对照研究。结果恶性多形性腺瘤的声像图特点与良性多形性腺瘤相似,但其肿瘤相对较大,质地更硬,内部回声分布更紊乱。不同性质的肿瘤的大小和质地有显著性差异,(P<0.01)。结论多形性腺瘤的超声诊断主要依据二维图像之特点。当多形性腺瘤大于3.0 cm,硬度较硬,内部回声分布不均多提示恶性。     

The role of the le fort I maxillotomy in the management of incompletely resected pituitary macroadenomas.

Objective: The options available for the treatment of a nonsecreting pituitary macroadenoma that has been incompletely resected include reoperation, fractionated radiation therapy, and radiosurgery. Reoperation in this setting may be hindered by the same obstacles that prevented a complete resection during the initial surgical procedure, and should prompt consideration of an alternate approach or exposure. Methods: Between January 1998 and December 2003, 10 consecutive patients were referred to the Department of Neurosurgery at the University of Texas Southwestern Medical Center for the evaluation of a nonsecreting pituitary macroadenoma that measured 3 cm or greater in diameter despite having undergone an attempt at a complete resection elsewhere. Each of these patients was reoperated using a Le Fort I maxillotomy to enhance the exposure provided by a traditional transsphenoidal approach. Results: A total or near total (> 95%) resection was achieved in each case. One patient required reoperation for the repositioning of a fat graft to treat a cerebrospinal fluid fistula and one patient experienced a worsening of anterior pituitary function postoperatively. Five patients noted improved vision and no patient experienced further visual loss. Three patients have required subsequent treatment of small foci of recurrent or progressing tumor with stereotactic radiation therapy. No patient has received fractionated radiation therapy. Conclusion: The added exposure provided by a Le Fort I maxillotomy facilitates the resection of pituitary macroadenomas that have been incompletely resected by a traditional transnasal, trans-sphenoidal approach.     

大鼠肾上腺细胞经胶原凝胶三维培养后进行同种移植的实验研究

Objective To investigate a novel method of adrenocotical cells transplantation. Methods Adrenal glands of neonate rats were dissociated into adrenal cortical cells. Cells were cultured in self-made collagen type Ⅰ gel for one week, and then transplanted under the renal capsule of bilateral adrenalectomy mate rats. Blood samples were collected per week after surgery. Animals were sacrificed at the 8th week, and histological characteristics of the allografts, proliferation of transplanted cells, CYP11B1 and CYP11B2 expression as well as plasma aldosterone and corticosterone were observed. Results There were totally 15 rats receiving collagen gel transplantation, and 12 survived 8 weeks post-operation. The plasma cortocosterone level in collagen gel transplantation group was significantly higher than in adrenocortical cell transplantation group, and reached the normal level from 6th to 8th week, but the change in plasma aldosterone level in collagen gel transplantation group was similar to that of adrenocortical cell transplantation group. The adrenocortical cells cultured in gel grew well, and had a high proliferation rate. 95% of them were fasciculata cells which expressed CYP11B1, and the rest were glomerulosa cells which expressed CYP11B2. No inflammatory cell infiltration was observed. Conclusion The proliferation and function of adrenocortical cells could be promoted when they were cultured in collagen gel.     

静脉性脑梗死动物模型的建立及相关研究

静脉性脑梗死动物模型的建立是通过不同的栓塞方法闭塞实验动物上矢状窦的不同部位，其目的是观察脑组织的血流量、血氧饱和度、脑组织水含量、脑灌注压、及各种影像学表现等参数指标的变化，从病理生理角度探讨静脉性脑梗死的发病机理及演变过程。     

后腹腔镜治疗肾上腺肿瘤35例临床分析

目的总结后腹腔镜技术治疗肾上腺肿瘤的临床经验.方法采用后腹腔镜切除肾上腺肿瘤35例,男12例,女23例.年龄25岁～72岁,平均49.8岁.左侧15例,右侧20例.其中嗜铬细胞瘤5例,原发性醛固酮增多症10,柯兴氏病2例,神经节细胞瘤2例,无功能性腺瘤16例.腰部取3个套管针穿刺入路,用自制的水囊扩张器扩张后腹腔,用超声刀将肿瘤切除.结果 35例手术均成功,无中转开放手术病例.术中出血量10～500 ml,平均74 ml.病人均未输血.手术时间45～200 min,平均90 min.结论后腹腔镜手术切除肾上腺肿瘤手术效果确切,手术时间短,术中出血少,损伤小,术后恢复快,可以替代绝大多数肾上腺肿瘤开放手术.     

Pituitary adenomas: Trans‐sphenoidal experience of 300 cases

Objective: The main aim of the present study was to examine the effectiveness and complication rate of the 1 cm right‐sided unilateral sublabial trans‐sphenoidal surgery for patients with pituitary adenoma equal to or greater than 5 mm in diameter. Method: A total of 350 patients were surgically treated for pituitary adenomas between December 1999 and December 2003 in an academic neurosurgical unit in China. Three hundred patients (86%) were treated with the 1‐cm right‐sided unilateral sublabial trans‐sphenoidal approach. The mean age of patients was 43 years (range 10–78 years) and female patients accounted for 59% of the total. One hundred and ninety‐six (64%) patients had functioning endocrine tumours and 104 (36%) patients had non‐functioning tumours or macroadenomas. Tumours which were outside this simple and basic classification were excluded from the study. Results: There were no operative mortalities. One patient developed hypopituitarism and 16 (5%) developed transient diabetes insipidus that required pituitrin treatment. The remission rate for macroadenoma was 85% and that for microadenoma was 98.5% during a medium term follow‐up of 1–5 years. One hundred and fifteen patients had prolactin secreting tumours and 90.4% achieved endocrine remission. Fifty‐six patients had growth hormone secreting tumours and 75.4% achieved endocrine remission. Preoperatively, one hundred and fifty‐one patients presented with visual impairment and 148 (98%) achieved a documented improvement in visual acuity. The mean duration of hospital stay was 4 days (range 3–7 days). Conclusion: This minimally invasive trans‐sphenoidal surgery for pituitary adenomas could be used as the primary treatment for small pituitary tumours. The effectiveness of the tumour removal and low morbidity rate compare favourably with the conventional sublabial approach as well as the more recently developed endoscopic endonasal approaches.     

Thyrotrophin-Releasing Hormone Raises Cytosolic Free Calcium Concentration in Human Adenomatous Somatotrophs and Corticotrophs; Comparison with in vivo Responsiveness to Thyrotrophin-Releasing Hormone in Patients with Acromegaly or Cushing's Disease

The effect of thyrotrophin-releasing hormone (TRH) on intracellular free Ca²⁺ concentration, [Ca²⁺)i, was investigated with the fluorescent dye fura-2 in cell suspensions obtained from 13 human growth hormone-secreting adenomas and 6 adrenocorticotrophin-secreting adenomas. Preoperatively, 9 out of 13 acromegalic patients showed a positive growth hormone response to TRH administration while none of the 6 patients with Cushing's disease had a plasma adrenocorticotrophin increase after TRH injection. In all the growth hormone-secreting adenomas the addition of TRH (100 nM) caused a significant rise in [Ca²⁺]i (from a resting level of 133±40 (±SD) to a value of 284±119 nM at 100 nM TRH, n = 42; P<0.001). The transient induced by TRH was found to have a dual origin, one due to Ca²⁺ mobilization from intracellular stores which was maintained in presence of EGTA (3mM) and verapamil (10 μM) and a plateau phase due to Ca²⁺ influx from the extracellular media. Somatostatin (0.1 μM) lowered both resting [Ca²⁺]i and TRH-induced transients. The effect of gonadotrophin-releasing hormone on [Ca²⁺]i was evaluated on cell suspensions obtained from 6 growth hormone-secreting adenomas. Gonadotrophin-releasing hormone (100 nM) caused a marked rise in [Ca²⁺]i (from 179±25 to 283±15nM) on the cell suspension obtained from the only in vivo responsive adenoma while it was ineffective in the remaining 5. Although TRH was ineffective in modifying plasma adrenocorticotrophin levels in all patients with Cushing's disease, in 5 out of 6 tumors the addition of 100 nM TRH caused a significant rise in [Ca²⁺]i (from 102.5 ± 36 to 163±66 nM, n = 22; P < 0.005). However, the effect of TRH on [Ca²⁺]i was significantly lower than that caused by arginine vasopressin, a physiological stimulator of adrenocorticotrophin release ([Ca²⁺]i values; 145±78 nM at 100 nM TRH versus 300±140 at 10 nM arginine vasopressin, n = 15; P<0.05). Moreover, the effect of arginine vasopressin on [Ca²⁺]i was detectable at concentrations as low as 0.1 nM while TRH was effective at concentrations higher than 1 nM. By contrast, gonadotrophin-releasing hormone was ineffective in increasing [Ca²]i in all the adrenocorticotrophin-secreting adenomas studied. Collectively, these data indicate that sensitivity to TRH is present in almost all the growth hormone- and adrenocorticotrophin-secreting adenomas independently of the responsiveness of the individual patients to the peptide.     

伽玛刀治疗垂体腺瘤126例的临床分析

目的 评价伽玛刀治疗垂体腺瘤的疗效和并发症.方法 对2000年8月至2005年12月间伽玛刀治疗垂体腺瘤并有完整临床资料.病人年龄15～76岁,肿瘤最大径<10mm 68例、10～20mm 56例、>20mm 2例,伽玛刀治疗剂处方量为15～30Gy、50%～65%等剂量曲线.结果 随访1～6年,肿瘤消失75例,肿瘤缩小28例,肿瘤无变化15例,肿瘤继续增大8例.肿瘤生长控制率93.6%(118/126);激素水平恢复正常率63%(49/78),垂体功能低下发生率为15%,因肿瘤复发或激素水平未恢复再行肿瘤切除术5例.结论 伽玛刀治疗垂体腺瘤,能控制垂体腺瘤肿瘤生长,可恢复垂体内分泌功能异常改变.     

25例垂体ACTH腺瘤的临床分析

目的分析和探讨垂体促肾上腺皮质激素(ACTH)腺瘤的临床特点和治疗方法。方法回顾性分析从2004年1月至2006年3月在我院接受治疗的25例垂体ACTH腺瘤患者的临床特点、治疗经过及预后。结果垂体ACTH腺瘤患者的临床症状和肿瘤的大小密切相关,微腺瘤(直径≤10 mm)患者以Cushing综合症征为主要临床表现,而大腺瘤(直径>10 mm)患者则以压迫症状为主。有无Cushing综合征的表现和腺瘤的直径呈负相关(P<0.05)。本组25例垂体ACTH腺瘤中21例具有侵袭性。垂体ACTH腺瘤患者主要以育后女性为主。该病首次经蝶手术后近期疗效显著。结论垂体ACTH大腺瘤以压迫症状为主,微腺瘤则以Cushing综合征表现为主。该肿瘤大多数具有侵袭性倾向,育后女性是高危人群。经蝶显微手术是垂体ACTH腺瘤的首选治疗方法。     

米非司酮试验在库欣综合征诊断上的应用

应用一次法口服４ｍｇ／ｋｇ的米非司酮（ＲＵ４８６）观察１７例单纯性肥胖和７例疑似库欣组的病人服药前后的反应，并与１０例正常人以及２９例库欣综合征病人进行比较，发现库欣综合征病人服药以后，血Ｆ２４小时尿Ｆ及血ＡＣＴＨ均无显著性变化（Ｐ〉０．０５），而其他三组各指标均升高（Ｐ〈０．０１）。并得出鉴别库欣综合征与非库欣综合征的标准为：血Ｆ增加的百分比为３０％２４小时尿Ｆ增加百分比为１８％，ＡＣＴＨ增加百